The FDA's Breakthrough Devices Program accelerates access to promising medical devices for serious conditions, ensuring safety and effectiveness through a rigorous review process. Haystack MRD test ...
Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for identifying patients ...
Medical Device Network on MSN
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval
The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results